Recent Updates
Recently added Catalysts

EB06

Phase 2

Non-Segmental Vitiligo (NSV) | Monoclonal antibody | Dermatology |Edesa Biotech, Inc.|Trials Updated: Oct 22, 2026

EB06 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2026

EB06 target and mechanism

Molecular targetCXCL10
Target classProtein
ModalityMonoclonal antibody

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment80

FDA Designations

No designations recorded

EB06 clinical trials

EB06 · 1 trial · 1 indication

Phase 2 1
NCT07889492A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental VitiligoNon-Segmental Vitiligo (NSV)
RECRUITING80 Analytics
PHASE2RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
Non-Segmental Vitiligo (NSV)
NCT0788949280
Unlock trial analytics

Study Endpoints

Primary Endpoints

Mean percent change from baseline in F-VASI at Week 28
28 Weeks

The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of facial vitiligo that combines the extent of facial involvement and degree of depigmentation. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo.

Secondary Endpoints

Mean percent change from baseline in F-VASI at Weeks 24 and 32
Weeks 24 and 32
Proportion of subjects achieving F VASI50 at Weeks 24, 28 and 32.
Weeks 24, 28, and 32
Time to achieving F-VASI50
Baseline through Week 32
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PlaceboPLACEBO_COMPARATOR -
EB06EXPERIMENTAL -

Interventions

NameTypeDescription
Placebo IVOTHERPlacebo IV
EB06BIOLOGICALEB06 IV loading 20 mg/kg followed by 10 mg/kg
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: 1. Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 5% total BSA, and ≥ 4 T-VASI. 2. Men and women ≥ 18 years of age at the time of consent. 3. Subjects who agree to discontinue all agents used to treat vitiligo...

Countries:Canada
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 22, 2026NCT07889492NEW_TRIAL: changed
LOWOct 22, 2026NCT07889492NEW_TRIAL: changed

Explore more on BiopharmaWatch

Edesa Biotech, Inc. (EDSA)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track